Skip to main content
Premium Trial:

Request an Annual Quote

CareDx Preliminary Q3 Revenues Up 57 Percent

NEW YORK – Transplant diagnostics company CareDx said on Wednesday after the close of the market that its preliminary third quarter revenues rose an estimated 57 percent year over year.

For the three months ended Sept. 30, revenues are expected to be approximately $53 million, up from $33.8 million in Q3 2019. Analysts are expecting revenues of $44.7 million for the quarter.

Testing revenues for the quarter are expected to be approximately $45.2 million, up from $28.2 million in the year-ago period. CareDx said it returned approximately 21,800 total AlloSure and AlloMap patient results during the quarter. Product revenues are expected to be $5.4 million, up from $4.2 million in Q3 2019. Digital & other revenues are expected to be $2.4 million, compared to $1.4 million in the year-ago quarter.

"Our strong third quarter performance was driven by this dedication and our commitment to lead in advancing transplantation, underscored by our surveillance solutions, AlloSure and AlloMap," CareDx Chairman and CEO Peter Maag said in a statement.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.